Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study.
Jardine AG, Holdaas H, Fellström B, Cole E, Nyberg G, Grönhagen-Riska C, Madsen S, Neumayer HH, Maes B, Ambühl P, Olsson AG, Holme I, Fauchald P, Gimpelwicz C, Pedersen TR; ALERT Study Investigators. Jardine AG, et al. Among authors: olsson ag. Am J Transplant. 2004 Jun;4(6):988-95. doi: 10.1111/j.1600-6143.2004.00445.x. Am J Transplant. 2004. PMID: 15147434 Free article. Clinical Trial.
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.
Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Holdaas H, et al. Among authors: olsson ag. Lancet. 2003 Jun 14;361(9374):2024-31. doi: 10.1016/S0140-6736(03)13638-0. Lancet. 2003. PMID: 12814712 Clinical Trial.
Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial.
Fellström B, Holdaas H, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Logan JO, Pedersen TR; Assessment of Lescol in Renal Transplantation Study Investigators. Fellström B, et al. Among authors: olsson ag. Kidney Int. 2004 Oct;66(4):1549-55. doi: 10.1111/j.1523-1755.2004.00919.x. Kidney Int. 2004. PMID: 15458450 Free article. Clinical Trial.
Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial.
Fellström B, Holdaas H, Jardine AG, Nyberg G, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Staffler B, Pedersen TR; Assessment of Lescol in Renal Transplantation Study Investigators. Fellström B, et al. Among authors: olsson ag. Transplantation. 2005 Jan 27;79(2):205-12. doi: 10.1097/01.tp.0000147338.34323.12. Transplantation. 2005. PMID: 15665769 Clinical Trial.
Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study.
Holdaas H, Fellström B, Cole E, Nyberg G, Olsson AG, Pedersen TR, Madsen S, Grönhagen-Riska C, Neumayer HH, Maes B, Ambühl P, Hartmann A, Staffler B, Jardine AG; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Holdaas H, et al. Among authors: olsson ag. Am J Transplant. 2005 Dec;5(12):2929-36. doi: 10.1111/j.1600-6143.2005.01105.x. Am J Transplant. 2005. PMID: 16303007 Free article. Clinical Trial.
Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data.
Holdaas H, Fellström B, Holme I, Nyberg G, Fauchald P, Jardine A, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Weinreich T, Olsson AG, Pedersen TR, Benghozi R, Hartmann A; ALERT Study Group. Assessment of Lescol in Renal Transplantation. Holdaas H, et al. Among authors: olsson ag. J Cardiovasc Risk. 2001 Apr;8(2):63-71. doi: 10.1177/174182670100800202. J Cardiovasc Risk. 2001. PMID: 11324372 Clinical Trial.
Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study.
Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Palmer G; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. Pedersen TR, et al. Among authors: olsson ag. Am J Cardiol. 2004 Sep 15;94(6):720-4. doi: 10.1016/j.amjcard.2004.06.003. Am J Cardiol. 2004. PMID: 15374773 Clinical Trial.
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. Pedersen TR, et al. Among authors: olsson ag. JAMA. 2005 Nov 16;294(19):2437-45. doi: 10.1001/jama.294.19.2437. JAMA. 2005. PMID: 16287954 Clinical Trial.
Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
Tikkanen MJ, Holme I, Cater NB, Szarek M, Faergeman O, Kastelein JJ, Olsson AG, Larsen ML, Lindahl C, Pedersen TR; Incremental DEcrease through Aggressive Lipid Lowering Investigators. Tikkanen MJ, et al. Among authors: olsson ag. Am J Cardiol. 2009 Mar 1;103(5):577-82. doi: 10.1016/j.amjcard.2008.10.029. Epub 2009 Jan 17. Am J Cardiol. 2009. PMID: 19231315 Clinical Trial.
314 results